Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 3/2014

01-03-2014 | Review Article

T-Cell Trafficking and Anti-Adhesion Strategies in Inflammatory Bowel Disease: Current and Future Prospects

Authors: Mahmoud H. Mosli, Jesus Rivera-Nieves, Brian G. Feagan

Published in: Drugs | Issue 3/2014

Login to get access

Abstract

The medical management of idiopathic inflammatory bowel disease (IBD) has historically been based upon the use of broad-spectrum anti-inflammatory drugs such as corticosteroids and thiopurines. Recently, the identification of novel mechanisms central to the pathophysiology of IBD has provided more specific targets, including inhibition of leukocyte trafficking to the gut. In this article, we discuss the molecular biology of intestinal leukocyte trafficking and review the emerging therapies that target this process, including vedolizumab, natalizumab, etrolizumab, PF-547659, alicaforsen, efalizumab, and emerging members of this class.
Literature
1.
2.
Kucharzik T, Maaser C, Lugering A, Kagnoff M, Mayer L, Targan S, et al. Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm Bowel Dis. 2006;12(11):1068–83.PubMedCrossRef
3.
Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427–34.PubMedCrossRef
4.
Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369(9573):1641–57 (*A comprehensive review of recently developed therapies for IBD).
5.
Cottone M, Renna S, Orlando A, Mocciaro F. Medical management of Crohn’s disease. Expert Opin Pharmacother. 2011;12(16):2505–25.PubMedCrossRef
6.
Cohen RD. Evolving medical therapies for ulcerative colitis. Current Gastroenterol Rep. 2002;4(6):497–505.CrossRef
7.
Ohkura N, Kitagawa Y, Sakaguchi S. Development and maintenance of regulatory T cells. Immunity. 2013;38(3):414–23.PubMedCrossRef
8.
Hogan SP, Waddell A, Fulkerson PC. Eosinophils in infection and intestinal immunity. Current Opin Gastroenterol. 2013;29(1):7–14.CrossRef
9.
Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nature Rev Immunol. 2011;11(8):519–31.CrossRef
10.
Skapenko A, Leipe J, Lipsky PE, Schulze-Koops H. The role of the T cell in autoimmune inflammation. Arthritis Res Therapy. 2005;7(Suppl 2):S4–14.CrossRef
11.
McGeachy MJ, Cua DJ. Th17 cell differentiation: the long and winding road. Immunity. 2008;28(4):445–53.PubMedCrossRef
12.
Troncone E, Marafini I, Pallone F, Monteleone G. Th17 cytokines in inflammatory bowel diseases: discerning the good from the bad. Int Rev Immunol. 2013;32(5–6):526–33.PubMedCrossRef
13.
Boden EK, Snapper SB. Regulatory T cells in inflammatory bowel disease. Current Opin Gastroenterol. 2008;24(6):733–41.CrossRef
14.
Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev. 2006;212:256–71.PubMedCrossRef
15.
Bruewer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM, et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol. 2003;171(11):6164–72.PubMed
16.
Salmi M, Jalkanen S. Cell-surface enzymes in control of leukocyte trafficking. Nature Rev Immunol. 2005;5(10):760–71.CrossRef
17.
Panes J, Granger DN. Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. Gastroenterology. 1998;114(5):1066–90.PubMedCrossRef
18.
Mora JR, von Andrian UH. T-cell homing specificity and plasticity: new concepts and future challenges. Trends Immunol. 2006;27(5):235–43.PubMedCrossRef
19.
Bargatze RF, Jutila MA, Butcher EC. Distinct roles of l-selectin and integrins alpha 4 beta 7 and LFA-1 in lymphocyte homing to Peyer’s patch-HEV in situ: the multistep model confirmed and refined. Immunity. 1995;3(1):99–108.PubMedCrossRef
20.
Brownlie RJ, Zamoyska R. T cell receptor signalling networks: branched, diversified and bounded. Nature Rev Immunol. 2013;13(4):257–69.CrossRef
21.
Schmidt S, Moser M, Sperandio M. The molecular basis of leukocyte recruitment and its deficiencies. Mol Immunol. 2013;55(1):49–58.PubMedCrossRef
22.
Sundd P, Pospieszalska MK, Cheung LS, Konstantopoulos K, Ley K. Biomechanics of leukocyte rolling. Biorheology. 2011;48(1):1–35.PubMedCentralPubMed
23.
Hunt SW 3rd, Harris ES, Kellermann SA, Shimizu Y. T-lymphocyte interactions with endothelium and extracellular matrix. Crit Rev Oral Biol Med Off Publ Am Assoc Oral Biol. 1996;7(1):59–86.CrossRef
24.
Rao RM, Shaw SK, Kim M, Luscinskas FW. Emerging topics in the regulation of leukocyte transendothelial migration. Microcirculation. 2005;12(1):83–9.PubMedCrossRef
25.
Takuwa Y, Okamoto Y, Yoshioka K, Takuwa N. Sphingosine-1-phosphate signaling in physiology and diseases. Biofactors. 2012;38(5):329–37.PubMedCrossRef
26.
27.
Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. The Journal of pharmacology and experimental therapeutics. 2009;330(3):864–75 (**This article is a very useful reference to help understand the pharmacological aspects of vedolizumab action).
28.
Hesterberg PE, Winsor-Hines D, Briskin MJ, Soler-Ferran D, Merrill C, Mackay CR, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology. 1996;111(5):1373–80.PubMedCrossRef
29.
Thomas S, Baumgart DC. Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis. Inflammopharmacology. 2012;20(1):1–18.PubMedCrossRef
30.
von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med. 2003;348(1):68–72.CrossRef
31.
Balcer LJ, Galetta SL, Calabresi PA, Confavreux C, Giovannoni G, Havrdova E, et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology. 2007;68(16):1299–304.PubMedCrossRef
32.
Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348(1):15–23.PubMedCrossRef
33.
O’Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, Murray RS, et al. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology. 2004;62(11):2038–43.PubMedCrossRef
34.
Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.PubMedCrossRef
35.
Berger JR. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Safety Int J Med Toxicol Drug Exp. 2010;33(11):969–83.CrossRef
36.
Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med. 2005;353(4):362–8.PubMedCrossRef
37.
Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, et al. Natalizumab for active Crohn’s disease. N Engl J Med. 2003;348(1):24–32.PubMedCrossRef
38.
Gordon FH, Hamilton MI, Donoghue S, Greenlees C, Palmer T, Rowley-Jones D, et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther. 2002;16(4):699–705.PubMedCrossRef
39.
Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn’s disease. Gastroenterology. 2001;121(2):268–74.PubMedCrossRef
40.
Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353(18):1912–25.PubMedCrossRef
41.
Feagan BG, McDonald JW, Rochon J, Laupacis A, Fedorak RN, Kinnear D, et al. Low-dose cyclosporine for the treatment of Crohn’s disease. The Canadian Crohn’s Relapse Prevention Trial Investigators. N Engl J Med. 1994;330(26):1846–51.PubMedCrossRef
42.
Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007;132(5):1672–83 (**An important study for readers to review regarding the efficacy of natalizumab).
43.
44.
Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology. 2012;78(22):1736–42.PubMedCrossRef
45.
Pinto M, Dobson S. BK and JC virus: a review. J Infect. 2013;68 Suppl 1: S2-8.
46.
Comar M, Delbue S, Lepore L, Martelossi S, Radillo O, Ronfani L, et al. Latent viral infections in young patients with inflammatory diseases treated with biological agents: prevalence of JC virus genotype 2. J Med Virol. 2013;85(4):716–22.PubMedCrossRef
47.
Kleinschmidt-Demasters BK, Miravalle A, Schowinsky J, Corboy J, Vollmer T. Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab. J Neuropathol Exp Neurol. 2012;71(7):604-17.
48.
Kane SV, Horst S, Sandborn WJ, Becker B, Neis B, Moscandrew M, et al. Natalizumab for moderate to severe Crohn’s disease in clinical practice: the Mayo Clinic Rochester experience. Inflamm Bowel Dis. 2012;18(12):2203-8.
49.
Takazoe M, Watanabe M, Kawaguchi T, Matsumoto T, Oshitani N, Hiwatashi N, Hibi T. Oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn’s disease—a randomized, double-blind, placebo-controlled trial. DDW, AGA. 2009;S1066.
50.
Feagan BG, McDonald J, Greenberg GR, Wild G, Pare P, Fedorak R, Landau SB, Brettman LR. An ascending dose trial of humanized A4B7 antibody in ulcerative colitis. Gastroenterology. 2000; 118(4 suppl 2): A874.
51.
Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med. 2005;352(24):2499–507 (**The first study to examine the effects of inhibiting alpha4beta7 as a therapeutic target for inflammatory bowel disease. Epub 2005/06/17. **This is an important clinical trial that illustrated the efficacy of vedolizumab in the treatment of UC).
52.
Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, et al. Treatment of active Crohn’s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2008;6(12):1370–7 (**A pivotal phase-II study. Epub 2008/10/03).
53.
Parikh A, Leach T, Wyant T, Scholz C, Sankoh S, Mould DR, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflammatory bowel diseases. 2011;18(8):1470–9 (**An important phase-IIb study that provided significant insight into the pharmacological profile of vedolizumab. Epub 2011/12/08).
54.
Parikh A, Fox I, Leach T, Xu J, Scholz C, Patella M, et al. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(8):1691-9
55.
Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.PubMedCrossRef
56.
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–21.PubMedCrossRef
57.
Sands BE, Feagan BG, Rutgeerts P, Colombel J-F, Sandborn WJ, Sy R, D’Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S. Vedolizumab induction therapy for patients with Crohn’s disease who failed tumor necrosis factor antagonist treatment. 2013 (In Press).
58.
Feagan B. Long-term safety of vedolizumab for the treatment of ulcerative colitis or Crohn’s disease. United Eur Gastroenterol Week (UEGW). 2013.
59.
Cepek KL, Parker CM, Madara JL, Brenner MB. Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells. J Immunol. 1993;150(8 Pt 1):3459–70.PubMed
60.
Rutgeerts PJ, Fedorak RN, Hommes DW, Sturm A, Baumgart DC, Bressler B, et al. A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut. 2013;62(8):1122-30
61.
Vermeire S, Ghosh S, Panes J, Dahlerup JF, Luegering A, Sirotiakova J, et al. The mucosal address in cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut. 2011;60(8):1068–75.PubMedCrossRef
62.
Philpott JR, Miner PB Jr. Antisense inhibition of ICAM-1 expression as therapy provides insight into basic inflammatory pathways through early experiences in IBD. Expert Opin Biol Ther. 2008;8(10):1627–32.PubMedCrossRef
63.
Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn’s disease. Gastroenterology. 1998;114(6):1133–42.PubMedCrossRef
64.
Schreiber S, Nikolaus S, Malchow H, Kruis W, Lochs H, Raedler A, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn’s disease. Gastroenterology. 2001;120(6):1339–46.PubMedCrossRef
65.
Yacyshyn BR, Barish C, Goff J, Dalke D, Gaspari M, Yu R, et al. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn’s disease. Aliment Pharmacol Ther. 2002;16(10):1761–70.PubMedCrossRef
66.
Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn’s disease. Gut. 2002;51(1):30–6.PubMedCrossRef
67.
van Deventer SJ, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB Jr. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther. 2006;23(10):1415–25.PubMedCrossRef
68.
Miner PB Jr, Wedel MK, Xia S, Baker BF. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment Pharmacol Ther. 2006;23(10):1403–13.PubMedCrossRef
69.
Miner P, Wedel M, Bane B, Bradley J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther. 2004;19(3):281–6.PubMedCrossRef
70.
71.
Kothary N, Diak IL, Brinker A, Bezabeh S, Avigan M. Dal Pan G. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol. 2011;65(3):546–51.PubMedCrossRef
72.
Eksteen B, Adams DH. GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn’s disease. IDrugs Invest Drugs J. 2010;13(7):472–781.
73.
74.
75.
Feagan BG, Sandborn W, D’Haens G, Lee SD, Allez M, Fedorak R, Seidler U, Vermeire S, Lawrance I, Jurgensen CH, Heath A, Chang DJ, For the SHIELD-1 Investigators. Vercirnon, an Oral CCR9 antagonist, as induction therapy in active Crohn’s disease: randomized, double-blind, placebo-controlled, Phase 3 Trial. San Deigo: ACG; 2013.
76.
Wermers JD, McNamee EN, Wurbel MA, Jedlicka P, Rivera-Nieves J. The chemokine receptor CCR9 is required for the T-cell-mediated regulation of chronic ileitis in mice. Gastroenterology. 2011;140(5):1526–5 e3 (Epub 2011/02/09).
77.
Wurbel MA, McIntire MG, Dwyer P, Fiebiger E. CCL25/CCR9 interactions regulate large intestinal inflammation in a murine model of acute colitis. PloS one. 2011;6(1):e16442 (Epub 2011/02/02).
78.
Rojas-Lopez AE, Soldevila G, Meza-Perez S, Dupont G, Ostoa-Saloma P, Wurbel MA, et al. CCR9 + T cells contribute to the resolution of the inflammatory response in a mouse model of intestinal amoebiasis. Immunobiology. 2012;217(8):795–807.PubMedCrossRef
79.
Mayer L, Sandborn WJ, Stepanov Y, Geboes K, Hardi R, Yellin M, et al. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2013 (Epub 5 Mar).
80.
81.
82.
Melzer N, Meuth SG. Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies. Clin Exp Immunol. 2013 (Epub 27 Aug).
83.
84.
Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870–80.PubMedCrossRef
85.
Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med. 2010;61:35–47.PubMedCrossRef
86.
Erle DJ, Briskin MJ, Butcher EC, Garcia-Pardo A, Lazarovits AI, Tidswell M. Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes. J Immunol. 1994;153(2):517–28.PubMed
87.
Parikh A FE, Soler D, Wyant T, Kadambi V, Leach T, Milch C, Fox I, (Millennium: The Takeda Oncology Company C, MA, US). Gastrointestinal selectivity of vedolizumab (MLN0002), a humanized monoclonal antibody to the alpha4beta7 integrin. CCF; Florida: Inflammatory Bowel Disease; 2008. p. S18 P–0025 (**An important study that highlights the gut selective properties of vedolizumab).
88.
Leclerc M, Lesesve JF, Gaillard B, Troussard X, Tourbah A, Debouverie M, et al. Binucleated lymphocytes in patients with multiple sclerosis treated with natalizumab. Leukemia Lymphoma. 2011;52(5):910–2.PubMedCrossRef
89.
Wyant TL, Sankoh S, Wang Y, Paolino J, Pasetti MF, Feagan BG, Parikh A. A phase 1, double-blind placebo-controlled single-dose study to determine the immune response to systemic and mucosal antigenic challenge in the presence of vedolizumab. ECCO. 2013;592 (abstract).
90.
Rivera-Nieves J, Gorfu G, Ley K. Leukocyte adhesion molecules in animal models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(12):1715–35.
Metadata
Title
T-Cell Trafficking and Anti-Adhesion Strategies in Inflammatory Bowel Disease: Current and Future Prospects
Authors
Mahmoud H. Mosli
Jesus Rivera-Nieves
Brian G. Feagan
Publication date
01-03-2014
Publisher
Springer International Publishing
Published in
Drugs / Issue 3/2014
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-013-0176-2

Other articles of this Issue 3/2014

Drugs 3/2014 Go to the issue

Letter to the Editor

Prevention of Postoperative Recurrence in Crohn’s Disease

Erratum

Erratum to: Oxycodone/Naloxone Prolonged-Release: A Review of Its Use in the Management of Chronic Pain While Counteracting Opioid-Induced Constipation

Adis Drug Evaluation

Oxycodone/Naloxone Prolonged-Release: A Review of Its Use in the Management of Chronic Pain While Counteracting Opioid-Induced Constipation

R&D Insight Report

Umeclidinium/Vilanterol: First Global Approval

Therapy in Practice

Drug Treatment of Hypertension in Pregnancy

Adis Drug Evaluation

Exenatide Twice Daily: A Review of Its Use in the Management of Patients with Type 2 Diabetes Mellitus